Press Release High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux team...
Gdańsk, Poland – 30 January 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing...
PRESS RELEASE – INSIDE INFORMATION BioSenic patent granted in Canada for broader protection of its ATO therapeutic platform Composition-of-matter...
— First medicine approved under new “1+” mechanism by HKSAR Government, providing an important treatment option to patients in Hong...
VANCOUVER, BC / ACCESSWIRE / January 30, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), announces it is...
HOUSTON, TX / ACCESSWIRE / January 29, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company...
SAN FRANCISCO, CA / ACCESSWIRE / January 29, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the...
CONSHOHOCKEN, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for...
ORION CORPORATION PRESS RELEASE 29 January 2024 at 15.00 EET Orion publishes Financial Statement Release for 2023 and holds a...
MENLO PARK, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...
WEST CHESTER, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology...
Shares to begin trading on NASDAQ on January 29, 2024 under the ticker symbol “AMIX” THE WOODLANDS, TX., Jan. 26,...
HANOVER, Md., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical...
SAN DIEGO and TORONTO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO, TSX:...
UC Davis Medical Center, a top regional and nationally ranked medical center, is the third academic center to participate in...
Q3W schedule of CRB-701 (SYS6002) demonstrates a 43% ORR and 71% DCR at predicted therapeutically relevant dosesAll assessable nectin-4 positive...
ORION CORPORATION PRESS RELEASE 26 JANUARY 2024 at 09.00 EET Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024Orion presented yesterday...
NEWTOWN SQUARE, Pa., Jan. 25, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to...
TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group"), a clinical-stage life science biotechnology company pioneering the...
TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (“Psyence Biomed”) is excited to announce the completion of its...